Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Lessons from Cuba for Global Precision Medicine: CYP2D6 Genotype Is Not a Robust Predictor of CYP2D6 Ultrarapid Metabolism.

Dorado P, González I, Naranjo ME, de Andrés F, Peñas-Lledó EM, Calzadilla LR, LLerena A.

OMICS. 2017 Jan;21(1):17-26. doi: 10.1089/omi.2016.0166.

PMID:
28271978
2.

High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies.

Naranjo ME, de Andrés F, Delgado A, Cobaleda J, Peñas-Lledó EM, LLerena A.

Pharmacogenomics J. 2016 Oct;16(5):485-90. doi: 10.1038/tpj.2016.47. Epub 2016 Jun 7.

PMID:
27272044
3.

High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina.

Moya G, Dorado P, Ferreiro V, Naranjo MEG, Peñas-Lledó EM, LLerena A.

Pharmacogenomics J. 2017 Jul;17(4):378-381. doi: 10.1038/tpj.2016.27. Epub 2016 Apr 12.

PMID:
27068265
4.

Worldwide interethnic variability and geographical distribution of CYP2C9 genotypes and phenotypes.

Céspedes-Garro C, Fricke-Galindo I, Naranjo ME, Rodrigues-Soares F, Fariñas H, de Andrés F, López-López M, Peñas-Lledó EM, LLerena A.

Expert Opin Drug Metab Toxicol. 2015;11(12):1893-905. doi: 10.1517/17425255.2015.1111871. Epub 2015 Nov 23. Review.

PMID:
26595139
5.

Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.

Fricke-Galindo I, Céspedes-Garro C, Rodrigues-Soares F, Naranjo ME, Delgado Á, de Andrés F, López-López M, Peñas-Lledó E, LLerena A.

Pharmacogenomics J. 2016 Apr;16(2):113-23. doi: 10.1038/tpj.2015.70. Epub 2015 Oct 27. Review.

PMID:
26503820
6.

Ethnic background and CYP2D6 genetic polymorphisms in Costa Ricans.

Céspedes-Garro C, Jiménez-Arce G, Naranjo ME, Barrantes R, Llerena A; CEIBA.FP Consortium of the Ibero-American Network of Pharmacogenetics & Pharmacogenomics RIBEF.

Rev Biol Trop. 2014 Dec;62(4):1659-71.

PMID:
25720195
7.

ABCB1 gene polymorphisms and violent suicide attempt among survivors.

Peñas-Lledó E, Guillaume S, Delgado A, Naranjo ME, Jaussent I, LLerena A, Courtet P.

J Psychiatr Res. 2015 Feb;61:52-6. doi: 10.1016/j.jpsychires.2014.12.005. Epub 2014 Dec 15.

PMID:
25543520
8.

Pharmacogenetics in Central American healthy volunteers: interethnic variability.

Céspedes-Garro C, Naranjo ME, Ramírez R, Serrano V, Fariñas H, Barrantes R, LLerena A; CEIBA Consortium of the Ibero-American Network of Pharmacogenetics and Pharmacogenomics RIBEF.

Drug Metab Pers Ther. 2015 Mar;30(1):19-31. Review.

PMID:
25490028
9.

High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme.

Apellániz-Ruiz M, Inglada-Pérez L, Naranjo ME, Sánchez L, Mancikova V, Currás-Freixes M, de Cubas AA, Comino-Méndez I, Triki S, Rebai A, Rasool M, Moya G, Grazina M, Opocher G, Cascón A, Taboada-Echalar P, Ingelman-Sundberg M, Carracedo A, Robledo M, Llerena A, Rodríguez-Antona C.

Pharmacogenomics J. 2015 Jun;15(3):288-92. doi: 10.1038/tpj.2014.67. Epub 2014 Nov 4.

PMID:
25348618
10.

Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations.

LLerena A, Naranjo ME, Rodrigues-Soares F, Penas-LLedó EM, Fariñas H, Tarazona-Santos E.

Expert Opin Drug Metab Toxicol. 2014 Nov;10(11):1569-83. doi: 10.1517/17425255.2014.964204. Review.

PMID:
25316321
11.

A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances.

Peñas-Lledó E, Guillaume S, Naranjo ME, Delgado A, Jaussent I, Blasco-Fontecilla H, Courtet P, LLerena A.

Pharmacogenomics J. 2015 Apr;15(2):172-6. doi: 10.1038/tpj.2014.42. Epub 2014 Aug 12.

PMID:
25113522
12.

CYP2D6 gene polymorphisms and predicted phenotypes in eight indigenous groups from northwestern Mexico.

Lazalde-Ramos BP, Martínez-Fierro Mde L, Galaviz-Hernández C, Garza-Veloz I, Naranjo ME, Sosa-Macías M, Llerena A.

Pharmacogenomics. 2014 Feb;15(3):339-48. doi: 10.2217/pgs.13.203.

PMID:
24533713
13.

CYP2D6 -1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers.

Llerena A, Dorado P, Ramírez R, Calzadilla LR, Peñas-Lledó E, Álvarez M, Naranjo ME, González I, Pérez B; CEIBA Consortium of Ibero–American Network of Pharmacogenetics & Pharmacogenomics RIBEF.

Pharmacogenomics. 2013 Dec;14(16):1973-7. doi: 10.2217/pgs.13.181.

PMID:
24279852
14.

Evaluation of drug-metabolizing enzyme hydroxylation phenotypes in Hispanic populations: the CEIBA cocktail.

de Andrés F, Sosa-Macías M, Lazalde-Ramos BP, Naranjo ME, Tarazona-Santos E, Llerena A; CEIBA.FP Consortium of the Ibero-American Network of Pharmacogenetics and Pharmacogenomics RIBEFa.

Drug Metabol Drug Interact. 2013;28(3):135-46. doi: 10.1515/dmdi-2013-0020. Review.

PMID:
23787463
15.

Impact of cytochrome P450 genes on suicide attempt and risk.

Peñas-Lledó EM, Naranjo ME, Llerena A.

Eur Arch Psychiatry Clin Neurosci. 2013 Dec;263(8):703-4. doi: 10.1007/s00406-013-0402-7. Epub 2013 Mar 16. No abstract available.

PMID:
23504002
16.

Losartan hydroxylation phenotype in an Ecuadorian population: influence of CYP2C9 genetic polymorphism, habits and gender.

Dorado P, Beltrán LJ, Machín E, Peñas-Lledó EM, Terán E, Llerena A; CEIBA.FP Consortium of the Ibero-American Network of Pharmacogenetics and Pharmacogenomics RIBEF.

Pharmacogenomics. 2012 Nov;13(15):1711-7. doi: 10.2217/pgs.12.160.

PMID:
23171336
17.

Development of a HPLC method for the determination of losartan urinary metabolic ratio to be used for the determination of CYP2C9 hydroxylation phenotypes.

Dorado P, Machín E, de Andrés F, Naranjo ME, Peñas-Lledó EM, Llerena A; CEIBA.FP Consortium for the Ibero-American Network of Pharmacogenomics RIBEF.

Drug Metabol Drug Interact. 2012;27(4):217-33.

PMID:
23093260
18.

High-performance liquid chromatography method using ultraviolet detection for the quantification of aripiprazole and dehydroaripiprazole in psychiatric patients.

Dorado P, de Andrés F, Naranjo ME, Peñas-Lledó EM, González I, González AP, de la Rubia A, Llerena A.

Drug Metabol Drug Interact. 2012;27(3):165-70. doi: 10.1515/dmdi-2012-0016.

PMID:
23089607
19.

CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients.

Peñas-Lledó EM, Trejo HD, Dorado P, Ortega A, Jung H, Alonso E, Naranjo ME, López-López M, Llerena A.

Mol Psychiatry. 2013 Jan;18(1):8-9. doi: 10.1038/mp.2012.91. Epub 2012 Jun 26. No abstract available.

PMID:
22733128
20.

Basal insulin and cardiovascular and other outcomes in dysglycemia.

ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S.

N Engl J Med. 2012 Jul 26;367(4):319-28. doi: 10.1056/NEJMoa1203858. Epub 2012 Jun 11.

Supplemental Content

Loading ...
Support Center